Rapid Antibiotic Combination Testing for Carbapenem-Resistant Gram-Negative Bacteria within Six Hours Using ATP Bioluminescence

被引:1
|
作者
Cai, Yiying [1 ,2 ]
Seah, Celene L. [1 ,2 ]
Leck, Hui [1 ]
Lim, Tze-Peng [1 ]
Teo, Jocelyn Q. [1 ,3 ]
Lee, Winnie [1 ]
Tan, Thuan-Tong [4 ]
Koh, Tse-Hsien [5 ]
Ee, Pui Lai Rachel [2 ]
Kwa, Andrea L. [1 ,2 ,6 ]
机构
[1] Singapore Gen Hosp, Dept Pharm, Singapore, Singapore
[2] Natl Univ Singapore, Dept Pharm, Singapore, Singapore
[3] Natl Univ Hlth Syst, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore
[4] Singapore Gen Hosp, Dept Infect Dis, Singapore, Singapore
[5] Singapore Gen Hosp, Dept Microbiol, Singapore, Singapore
[6] Duke NUS Med Sch, Emerging Infect Dis, Singapore, Singapore
基金
英国医学研究理事会;
关键词
in vitro combination testing; luciferin-luciferase reaction; multidrug resistance; CRITICALLY-ILL PATIENTS; POPULATION PHARMACOKINETICS; SUSCEPTIBILITY TESTS; POLYMYXIN-B; PHARMACODYNAMICS; IMIPENEM; COLISTIN;
D O I
10.1128/AAC.00183-18
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To guide the timely selection of antibiotic combinations against carbapenem-resistant Gram-negative bacteria (CR-GNB), an in vitro test with a short turnaround time is essential. We developed an in vitro ATP bioluminescence assay to determine effective antibiotic combinations against CR-GNB within 6 h. We tested 42 clinical CR-GNB strains (14 Acinetobacter baumannii, 14 Pseudomonas aeruginosa, and 14 Klebsiella pneumoniae strains) against 74 single antibiotics and two-antibiotic combinations. Bacteria (approximately 5 log(10) CFU/ml) were incubated with an antibiotic(s) at 35 degrees C; ATP bioluminescence was measured at 6 h and 24 h; and the measurements were compared to viable counts at 24 h. Receiver operating characteristic (ROC) curves were used to determine the optimal luminescence thresholds (T-RLU) for distinguishing between inhibitory and noninhibitory combinations. The areas under the 6-h and 24-h ROC curves were compared using the DeLong method. Prospective validation of the established thresholds was conducted using 18 additional CR-GNB. The predictive accuracy of T-RLU for the 6-h ATP bioluminescence assay was 77.5% when all species were analyzed collectively. Predictive accuracies ranged from 73.7% to 82.7% when each species was analyzed individually. Upon comparison of the areas under the 6-h and 24-h ROC curves, the 6-h assay performed significantly better than the 24-h assay (P < 0.01). Predictive accuracy remained high upon prospective validation of the 6-h ATP assay (predictive accuracy, 79.8%; 95% confidence interval [CI], 77.6 to 81.9%), confirming the external validity of the assay. Our findings indicate that our 6-h ATP bioluminescence assay can provide guidance for prospective selection of antibiotic combinations against CR-GNB in a timely manner and may be useful in the management of CR-GNB infections.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Whole-Genome Sequencing Snapshot of Clinically Relevant Carbapenem-Resistant Gram-Negative Bacteria from Wastewater in Serbia
    Cirkovic, Ivana
    Muller, Bruno H.
    Janjusevic, Ana
    Mollon, Patrick
    Istier, Valerie
    Mirande-Meunier, Caroline
    Brkic, Snezana
    ANTIBIOTICS-BASEL, 2023, 12 (02):
  • [42] Inhalation with intravenous loading dose of colistin in critically ill patients with pneumonia caused by carbapenem-resistant gram-negative bacteria
    Choe, Junsu
    Sohn, You Min
    Jeong, Suk Hyeon
    Park, Hyo Jung
    Na, Soo Jin
    Huh, Kyungmin
    Suh, Gee Young
    Jeon, Kyeongman
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [43] Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings?
    Apisarnthanarak, Anucha
    Hsu, Li Yang
    Khawcharoenporn, Thana
    Mundy, Linda M.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2013, 11 (02) : 147 - 157
  • [44] Tracking Colistin-Treated Patients to Monitor the Incidence and Outcome of Carbapenem-Resistant Gram-Negative Infections
    Kadri, Sameer S.
    Hohmann, Samuel F.
    Orav, E. John
    Bonne, Stephanie L.
    Moffa, Matthew A.
    Timpone, Joseph G.
    Strich, Jeffrey R.
    Palmore, Tara
    Christopher, Kenneth B.
    Varughese, Christy
    Hooper, David C.
    Danner, Robert L.
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (01) : 79 - 87
  • [45] An area under the concentration-time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria
    Yang, Jing
    Liu, Shaohua
    Lu, Jingli
    Sun, Tongwen
    Wang, Peile
    Zhang, Xiaojian
    CRITICAL CARE, 2022, 26 (01)
  • [46] Intravenous Colistin Monotherapy versus Combination Therapy against Carbapenem-Resistant Gram-Negative Bacteria Infections: Meta-Analysis of Randomized Controlled Trials
    Cheng, I-Ling
    Chen, Yu-Hung
    Lai, Chih-Cheng
    Tang, Hung-Jen
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (08)
  • [47] Predictive factors for 30-day mortality after polymyxin B treatment of carbapenem-resistant Gram-negative bacilli infections
    Zhou, Simin
    Luo, Xuemei
    Cheng, Shuo
    Shulai, Xinyue
    Zhou, Huimin
    Ge, Weihong
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2025, 154
  • [48] Treatment outcome and adverse effects of colistin in adult patients with carbapenem-resistant gram-negative bacteremia from Pakistan
    Babar, Zaheer Udin
    Dodani, Sunil Kumar
    Nasim, Asma
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 106 : 171 - 175
  • [49] Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Carbapenem-Resistant Gram-Negative Bacterial Infections Among Chinese Children
    Jia, Xuedong
    Yin, Zhao
    Zhang, Wan
    Guo, Conghui
    Du, Shuzhang
    Zhang, Xiaojian
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [50] Tigecycline-Based Regimens for Complicated Urinary Tract Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria: Case Series
    Niculae, Cristian-Mihail
    Gorea, Maria-Evelina
    Tirlescu, Laura-Georgiana
    Matoru, Raluca-Mihaela
    Hristea, Adriana
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)